Trial reportHuman vaccines & immunotherapeutics2013
Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.
Trial report in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Vaccines for preventing herpes zoster in older adults.The Cochrane database of systematic reviews · 2023Pooled it
- Vaccines for preventing herpes zoster in older adults.The Cochrane database of systematic reviews · 2019Pooled it
- Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis.BMJ (Clinical research ed.) · 2018Pooled it
- Vaccines for preventing herpes zoster in older adults.The Cochrane database of systematic reviews · 2016Pooled it
- TLR9 and STING agonists adjuvanted varicella-zoster virus glycoprotein E induced a potent and durable nasal vaccine response.Human vaccines & immunotherapeutics · 2026Article
- The Reduced Immunogenicity of Zoster Vaccines in CMV-Seropositive Older Adults Correlates with T Cell Imprinting.Vaccines · 2025Article
- Establishment of Safety Monitoring System for Vaccines Not Included in the National Immunization Program in Korea.Journal of Korean medical science · 2024Article
- The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.The Journal of infectious diseases · 2021Article
- Vaccination for quality of life: herpes-zoster vaccines.Aging clinical and experimental research · 2021Review
- A rare case of cellulitis after tetanus toxoid (TT) vaccination.Journal of family medicine and primary care · 2020Article
- Varicella and herpes zoster vaccine development: lessons learned.Expert review of vaccines · 2017Review
- Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.Human vaccines & immunotherapeutics · 2017Article
- Herpes zoster vaccine (Zostavax®): Cellulitic injection site reaction or bacterial cellulitis?Human vaccines & immunotherapeutics · 2017Article
- Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016Review
- Vaccination of healthcare workers: A review.Human vaccines & immunotherapeutics · 2015Review
- Cost-effectiveness of vaccination against herpes zoster.Human vaccines & immunotherapeutics · 2014Review
- Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.BMC health services research · 2013Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disease protection provided by herpes zoster (HZ) vaccination tends to reduce as age increases. This study was designed to ascertain whether a second dose of the HZ vaccine, Zostavax(®), would increase varicella zoster virus (VZV)-specific immune response among individuals aged ≥ 70 y. Individuals aged ≥ 70 y were randomized to receive HZ vaccine in one of three schedules: a single dose (0.65 mL), two doses at 0 and 1 mo, or two doses at 0 and 3 mo. VZV antibody titers were measured at baseline, 4 weeks after each vaccine dose, and 12 mo after the last dose. In total, 759 participants (mean age 76.1 y) were randomized to receive vaccination. Antibody responses were similar after a single dose or two doses of HZ vaccine [post-dose 2/post-dose 1 geometric mean titer (GMT) ratios for the 1-mo or 3-mo schedules were 1.11, 95% confidence interval (CI) 1.02-1.22 and 0.78, 95% CI 0.73-0.85], respectively). The 12-mo post-dose 2/12-mo post-dose 1 GMT ratio was similar for the 1-mo schedule and for the 3-mo schedule (1.06, 95% CI 0.96-1.17 and 1.08, 95% CI 0.98-1.19, respectively). Similar immune responses were observed in participants aged 70-79 y and those aged ≥ 80 y. HZ vaccine was generally well tolerated, with no evidence of increased adverse event incidence after the second dose with either schedule. Compared with a single-dose regimen, two-dose vaccination did not increase VZV antibody responses among individuals aged ≥ 70 y. Antibody persistence after 12 mo was similar with all three schedules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.